Dr. Retsch-Bogart is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 MacNider Hall, CB 7217
333 S. Columbia St.
Chapel Hill, NC 27599Phone+1 919-966-1055Fax+1 919-966-6179
Summary
- Dr. George Retsch-Bogart, MD, is a specialist in Pediatric Pulmonology based in Chapel Hill, NC with extensive experience in cystic fibrosis, clinical research, healthcare outcomes research, pseudomonal lung infections, and anti-bacterial agents. He completed his residency in Pediatrics at the University of Minnesota and his fellowship in Pediatric Pulmonology at the University of North Carolina Hospitals. Since 1989, he has been on faculty of the Department of Pediatrics at the University of North Carolina at Chapel Hill School of Medicine, moving to Emeritus Professor status in July 2024. Dr. Retsch-Bogart has significantly contributed to clinical research, with multiple published papers and participation in several clinical trials focused mainly on cystic fibrosis. His work has been recognized with honors and awards such as those from the American Pediatric Society and the American Academy of Pediatrics.
Education & Training
University of North Carolina HospitalsFellowship, Pediatric Pulmonology, 1986 - 1989
University of MinnesotaResidency, Pediatrics, 1978 - 1981
University of Cincinnati College of MedicineClass of 1978
Certifications & Licensure
NC State Medical License 1986 - 2024
MN State Medical License 1980 - 1987- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Pulmonology
Awards, Honors, & Recognition
- American Pediatric Society 2018
- Regional Top Doctor Castle Connolly, 2014
- Fellow of American Academy of Pediatrics American Academy of Pediatrics
- Join now to see all
Clinical Trials
- A Study of the Safety and Efficacy of Tobramycin for Inhalation in Young Children With Cystic Fibrosis Start of enrollment: 2000 Feb 01
- Comparison of Two Treatment Regimens to Reduce PA Infection in Children With Cystic Fibrosis Start of enrollment: 2004 Sep 01
- Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection Start of enrollment: 2003 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- 103 citationsEarly anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.Miriam M. Treggiari, Margaret Rosenfeld, Nicole Mayer-Hamblett, George Z. Retsch-Bogart, Ronald L. Gibson
Contemporary Clinical Trials. 2009-05-01 - 72 citationsInitial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.Nicole Mayer-Hamblett, Richard A. Kronmal, Ronald L. Gibson, Margaret Rosenfeld, George Z. Retsch-Bogart
Pediatric Pulmonology. 2012-02-01 - 83 citationsDuration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosisRonald L. Gibson, Julia Emerson, Nicole Mayer-Hamblett, Jane L. Burns, Sharon McNamara
Pediatric Pulmonology. 2007-07-01
Grant Support
- Phase III Placebo Controlled--Tobramycin Inhalation In Cystic Fibrosis PatientsNational Center For Research Resources1997
- Aerosolized Nucleotides (Atp/Utp) As New Therapy For CF Lung DiseaseNational Center For Research Resources1996–1997
Professional Memberships
- Fellow
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
